drugset / Trial / NCT07187661

Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis

NCT07187661

Completed 18 enrolled Khyber Medical University Peshawar
NaSingle-groupOpen-labelTreatment

Summary

Hemophilia is an inherited bleeding disorder characterized by deficiency of clotting factors, leading to increased bleeding tendencies. The most common complications are joint bleeds (hemarthroses), which cause chronic changes in joints and ultimately disability. Recurrent hemarthroses often result from chronic synovitis in target joints of patients with hemophilia, a process driven by Vascular Endothelial Growth Factor (VEGF) mediated pathological angiogenesis. Intra-articular administration of Bevacizumab, a VEGF neutralizing monoclonal antibody, may block this process and reduce the frequency of recurrent joint bleeds. This study evaluates the efficacy and safety of intra-articular Bevacizumab for preventing recurrent hemarthrosis in patients with hemophilia and chronic synovitis.

Timeline

Start
2025-09-09
Primary completion
2026-03-28
Completion
2026-04-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 20 mg Other
Subject Bevacizumab Monoclonal antibody 40 mg Other

Indications